Bloomage Biotech(SH:688363) Xi Niu Cai Jing·2026-01-09 03:57Group 1 - The core point of the news is that Shanghai Jiakai Biological Co., Ltd. has responded to the first round of inquiry from the Beijing Stock Exchange regarding compliance issues related to equity changes, control stability, product quality risks, and the sustainability of performance growth [2][4] Group 2 - Jiakai Biological was established in 2015 and focuses on the research, production, and sales of cosmetic functional raw materials, primarily used in skincare, masks, and hair care products [4] - The company plans to raise 310 million yuan through its IPO, which will be fully allocated to a project for annual production of 50 tons of functional plant extracts [4] - The company has seen significant valuation growth, from 3 billion yuan in 2020 to 24.7 billion yuan in 2025, reflecting an increase of over 7 times in five years [5] Group 3 - Revenue figures for Jiakai Biological from 2023 to the first three quarters of 2025 are 218 million yuan, 242 million yuan, and 195 million yuan, with year-on-year changes of 19.1%, 11.46%, and 7.91% respectively [5] - Net profit for the same period is 48 million yuan, 57 million yuan, and 47 million yuan, with year-on-year changes of -12.82%, 19.83%, and 16.91% respectively [5]